Featured15 November 2026Neuroendocrine tumours: SSTR imaging and PRRTRadioembolisation (TARE / SIRT)

Does giving Lu-177 DOTATATE through the hepatic artery make a difference in liver metastases?

The idea is circulating again on social media: giving the radiopeptide through a catheter in the hepatic artery instead of a vein. This article reviews four studies. LUTIA (Ebbers et al., the Netherlands, 2023-2024), the only randomised trial on the question, found no clinically meaningful increase in tumour uptake; Bodei et al. (Memorial Sloan Kettering, New York), published in November 2026, reported in a 10-patient prospective study a more than threefold higher dose to liver metastases by combining the arterial and intravenous routes in sequence.

AortaCoeliac trunkCommon hepatic a.Proper hepatic a.Right hepatic a.Left hepatic a. (II, III)Catheter tipLu-177 DOTATATE (illustrative)Metastasis
Figure 1. Hepatic arterial administration: catheter tip in the proper hepatic artery; on the first pass the drug reaches arterially supplied metastases. Schematic, not to scale; same anatomy as the site's TARE liver map. Lesion positions and dots are illustrative.

Why the artery?

PRRT with Lu-177 DOTATATE prolongs progression-free survival in grade 1-2 gastroenteropancreatic neuroendocrine tumours, but it has been less effective in patients with extensive or bulky liver metastases 1. Liver metastases draw most of their blood from the hepatic artery, the same principle behind Y-90 radioembolisation. Giving the radiopeptide into the hepatic artery aims to deliver more of it to the metastases on the first pass and so raise the tumour dose 1,2.

Which studies are reviewed?

  • LUTIA — Ebbers et al., Eur J Nucl Med Mol Imaging (online October 2023, print 2024) [1]: Multicentre in the Netherlands (UMC Utrecht, Netherlands Cancer Institute, Erasmus MC). Randomised controlled; in each patient one liver lobe was treated intra-arterially and the other lobe served as the same patient's control. 27 patients. The protocol was published in Trials in 2020 2.
  • Bodei et al., J Nucl Med (November 2026) [5]: Memorial Sloan Kettering Cancer Center, New York. Single-arm prospective clinical trial; 10 consecutive patients; two intra-arterial cycles followed by two intravenous cycles.
  • Puranik et al., Indian J Nucl Med (2024) [3]: Tata Memorial Centre, Mumbai (India). Prospective series; 14 patients; early efficacy and toxicity.
  • Limouris et al., Q J Nucl Med Mol Imaging (2012) [4]: Aretaieion Hospital, University of Athens (Greece; the "ARETAIEION protocol"). Single-arm series; 12 patients; super-selective hepatic arterial infusion.
05101520Intra-arterially treated lobe17.4Control lobe16.2Tumour / normal liver uptake ratio
Figure 2. LUTIA primary endpoint: tumour-to-normal-liver uptake ratio on SPECT/CT 24 hours after cycle 1 (two lobes in the same patient; p = 0.299) 1.

What does the evidence say?

  • LUTIA, Ebbers et al. (randomised controlled trial): In 27 patients with bilobar liver metastases, one lobe was treated intra-arterially for four cycles while the other lobe and extrahepatic disease were treated by the circulating drug (second pass), so the contralateral lobe served as a within-patient control. The primary endpoint was the tumour-to-normal-liver uptake ratio on SPECT/CT 24 hours after the first cycle: 17.4 in the intra-arterially treated lobe and 16.2 in the control lobe (p = 0.299), a mean increase of 17% (95% CI 1.00-1.37). The authors conclude that the approach is safe but does not produce a clinically significant increase in tumour uptake 1.
  • Bodei et al., J Nucl Med November 2026 (single-arm prospective study): Ten patients with progressive, nonresectable, liver-dominant gastroenteropancreatic NETs received four cycles two months apart: the first two through the hepatic arteries (activity adjusted to liver volume), the last two intravenously. Intra-arterial administration was feasible in 100% of patients; staff and patient exposure stayed within regulatory limits, with no contamination. On dosimetry the intra-arterial cycle (cycle 1) delivered more than three times the dose to liver metastases of the intravenous route (cycle 3); the authors note that the interim treatment response may have contributed to this difference. On Ga-68 DOTATATE PET, median liver lesion uptake rose by 86% with intra-arterial administration. Partial response was reported in 67% of patients 3 months after the end of treatment and in 87% at 6 months (RECIST and volumetric criteria); one severe adverse event (a lower oesophageal tear) occurred and was not attributed to the route 5. There is no control arm and the cohort is small.
  • Puranik et al. (2024) and Limouris et al. (2012) (single-arm series): In the prospective series of Puranik et al. (Mumbai, 14 patients), patients received 1-3 cycles of 7.4 GBq (200 mCi) intra-arterially; at 8 weeks, 9 had partial response and 5 stable disease 3. In the series of Limouris et al. (Athens, 12 patients; 7.4 GBq, 200 mCi, per session, up to six sessions), 8 had partial response, with grade 2-3 bone marrow toxicity in 75% 4. These series are small and have no comparison arm.

What it means for practice

Intravenous administration remains standard. The arterial route is being explored for liver-dominant disease within studies; the high response rates in single-arm series should be read alongside the small, non-significant difference in tumour uptake in the randomised comparison 1,3,4. A personalised schedule combining the arterial and intravenous routes in sequence has shown promising early results that still need confirmation in comparative studies 5. This article summarises what the evidence says; treatment decisions rest on guidelines and multidisciplinary review.

Test yourself

  1. What was the primary endpoint of the LUTIA trial, and what was the result?

  2. What principle underlies giving the radiopeptide into the hepatic artery?

  3. When interpreting the more than threefold dose difference in Bodei et al. (J Nucl Med 2026), what should be kept in mind?

References

  1. Ebbers SC, Barentsz MW, de Vries-Huizing DMV, et al. Intra-arterial peptide-receptor radionuclide therapy for neuro-endocrine tumour liver metastases: an in-patient randomised controlled trial (LUTIA). Eur J Nucl Med Mol Imaging. 2024;51(4):1121-1132 (online 2023). doi:10.1007/s00259-023-06467-y PMID 37897617
  2. Ebbers SC, et al. Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial). Trials. 2020;21:141. doi:10.1186/s13063-019-3888-0
  3. Puranik AD, Rangarajan V, Shetty NS, et al. Intra-arterial PRRT with Lu-177 DOTATATE in liver-dominant metastatic neuroendocrine tumors: early assessment of efficacy and toxicity. Indian J Nucl Med. 2024;39(2):71-76. doi:10.4103/ijnm.ijnm_7_23 PMID 38989301
  4. Limouris GS, Karfis I, Chatzioannou A, et al. Super-selective hepatic arterial infusions as established technique ('ARETAIEION' protocol) of [177Lu]DOTA-TATE in inoperable neuroendocrine liver metastases of gastro-entero-pancreatic (GEP) tumors. Q J Nucl Med Mol Imaging. 2012;56(6):551-8. PMID 23358409
  5. Bodei L, Ziv E, Mauguen A, Zanzonico P, et al. Optimizing the therapeutic index: sequential intraarterial-intravenous PRRT with personalized volumetric-adjusted dosing. J Nucl Med. 2026;67(11):1781-1788. doi:10.2967/jnumed.126.272710 PMID 42785954
Citing this piece

If you use this piece in a presentation, paper or thesis, add this line to your reference list (Vancouver style). "Copy" puts it on your clipboard; to cite the studies it reviews, use the numbered references above.

Nuclear Medicine Explained. Does giving Lu-177 DOTATATE through the hepatic artery make a difference in liver metastases? [Internet]. Last updated 15 November 2026. Available from: https://nuclearmedicineexplained.com/en/updates/intra-arterial-lu-177-dotatate

Published after physician editor approval · last updated 15 November 2026

Revision history
  1. 15 November 2026: First version: LUTIA, Puranik and Limouris series.
  2. 15 November 2026: Added Bodei et al. (J Nucl Med 2026) sequential intra-arterial-intravenous study; published after physician editor approval.
  3. 15 November 2026: Added three "Test yourself" questions (approved by the physician editor).
  4. 15 November 2026: The four reviewed studies are now named with authors, journal, year, centre and design ("Which studies are reviewed?"); the studies in the questions appear by name in the text (at the physician editor's request). Details verified on PubMed.

Prepared by Claude from primary sources and published after approval by the physician editor. It summarises what the evidence says; it is not a treatment recommendation.